Aylward R Bruce, Maher Chris
Global Polio Eradication Initiative, WHO, 20 Avenue Appia, Geneva 1211, Switzerland.
Biologicals. 2006 Jun;34(2):133-9. doi: 10.1016/j.biologicals.2006.02.012. Epub 2006 May 8.
Since the launch of the Global Polio Eradication Initiative (GPEI) in 1988, knowledge as to the nature of circulating polioviruses and the challenges to their interruption has increased tremendously, particularly during the period 2000-2005. By January 2006, however, the systematic application of the standard polio eradication strategies, combined with recent refinements, had reduced the number of countries with ongoing transmission of indigenous wild polioviruses to just four (Nigeria, India, Pakistan, and Afghanistan), the lowest ever in history. In addition, only 8 of the 22 areas that had been re-infected by wild poliovirus in 2003-2005 still required large-scale 'mop-up' activities and circulating vaccine-derived poliovirus (cVDPV) outbreaks were being readily addressed. This progress, despite new challenges late in the GPEI, was greatly facilitated by a range of solutions that included two new monovalent oral polio vaccines (mOPVs), new and robust international standards for polio outbreak response, and renewed political commitment across the remaining infected countries.
自1988年全球根除脊髓灰质炎行动(GPEI)启动以来,人们对传播中的脊髓灰质炎病毒的性质及其阻断面临的挑战的了解大幅增加,尤其是在2000年至2005年期间。然而,到2006年1月,标准的脊髓灰质炎根除策略的系统应用,再加上最近的改进措施,已将仍有本土野生脊髓灰质炎病毒传播的国家数量减少到仅四个(尼日利亚、印度、巴基斯坦和阿富汗),这是历史上的最低水平。此外,在2003 - 2005年被野生脊髓灰质炎病毒重新感染的22个地区中,只有8个地区仍需要大规模的“扫荡”活动,并且疫苗衍生脊髓灰质炎病毒(cVDPV)疫情也得到了及时应对。尽管在全球根除脊髓灰质炎行动后期出现了新的挑战,但这一进展得益于一系列解决方案,包括两种新的单价口服脊髓灰质炎疫苗(mOPV)、针对脊髓灰质炎疫情应对的新的有力国际标准,以及其余受感染国家重新做出的政治承诺。